IVIVI TECHNOLOGIES REPORTS FISCAL 07 50% INCREASE IN REVENUE.

Ivivi Technologies, Inc. (AMEX:II), Northvale, N.J., a leader in non-invasive, electrotherapeutic technologies, has announced financial results for fiscal year ended March 31, 2007.

For the fiscal year ended March 31, 2007, Ivivi Technologies reported total revenue of $1,182,340, a 50% increase from $786,512 reported for the fiscal year ended March 31, 2006. Revenues were primarily driven by rental programs in the wound care market and the sale of our products through distributors into medical facilities. Unit sales increased to $416,292 from $147,949 in fiscal 2006 while rentals increased to $740,006 from $638,563. The company also recorded licensing fee revenue of $26,042 in fiscal 2007 related to milestone payments received from Allergan and amortized over the initial term of our agreement with Allergan. The company had a net loss of $7,778,611, or $1.13 per share, for fiscal 2007 compared to a net loss of $10,746,671, or $2.26 per share, for fiscal 2006. The fiscal 2007 net loss reflects share based compensation expenses of approximately $2.1 million. In fiscal 2006, the net loss was impacted by a $4.7 million charge for the change in fair value of warrant and registration rights liabilities related to securities issued in the company's private placements.

For the three month period ended March 31, 2007, Ivivi Technologies reported total revenue of $369,166 compared to $308,238 in the comparable period in 2006, an increase of 20%. The current quarter included unit sales of $196,060 and rental revenue of $157,481. The company also recorded $15,625 in licensing revenues in the current quarter related to the amortization of milestone payments received from Allergan. This compares to unit sales of $51,673 and rental revenue of $256,565 in the comparative prior period. Net loss for the three month period ended March 31, 2007 was $1,422,943, or $0.15 per share, compared to a net loss of $6,705,239, or $1.41 per share, for the three month period ended March 31, 2006. The net loss in the prior year period included a $4.7 million charge for the change in fair value of warrant and registration rights liabilities related to securities issued in the company's private placements.

On March 31, 2007, Ivivi Technologies had cash and cash equivalents of $8.3 million, no outstanding long term debt and 9,556,783 common shares outstanding.

"It has been a year of significant progress, highlighted by the completion of our IPO last October, the signing of our exclusive worldwide distribution agreement with Allergan, as well as the receipt of marketing approval in Canada and the European Union for our non-invasive treatment for the promotion of wound healing, reduction of pain and post operative edema," commented Andrea A. DiMino, vice chairman and co-chief executive officer. "We have also made major strides to further demonstrate the efficacy and broad potential of our proprietary PEMF technology."

"Our cardiac study at the Cleveland Clinic Florida, where we are non-invasively treating patients with ischemic cardiomyopathy, is at full enrollment. Published studies have shown that our PEMF technology can enhance blood flow and stimulate angiogenesis (growth of new blood vessels) in animals and we are hopeful that our technology can make a difference in the lives of the patients in our study. Results of our cardiac study are expected toward the end of calendar 2007, although there can be no assurance of the timing of these results. Our PEMF technology has recently been shown to accelerate pain relief by 80% post-surgically after breast augmentation. With respect to our neurological research, Dr. Diana Casper of Albert Einstein College of Medicine demonstrated that our PEMF signals can double neuron survival in animals subjected to brain inflammation, which could lend itself to applications in Parkinson's disease and other neurodegenerative conditions in humans."

David Saloff, president and co-chief executive officer added, "With the groundwork we have laid over the past year, raising additional capital, advancing our science, further demonstrating clinical efficacy and also commencing the seeding of our initial target markets, we believe we are well positioned to attract additional partners to accelerate sales. Allergan, our worldwide distribution partner in the aesthetic and bariatric surgery markets, is involved in their premarketing launch activities and, although there can be no assurance, they are expected to launch our product later this year. We are also in active discussions for a partner for the chronic wound care market and have engaged several domestic third party distributors to assist us in further penetrating this market. We have also completed initial prototypes of a non-invasive, non-pharmacologic alternative to pain relievers such as non-steroidal anti-inflammatory drugs for inflammatory conditions and expect to file a 510(k) application by calendar year end for both a prescription and over-the-counter pain relief product."

About Ivivi Technologies, Inc.

Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The company's Electroceuticals have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.

For more information, visit http://www.ivivitechnologies.com or call 212/554-5469.